Clinical and biological features of five patients re-treated with rituximab for relapse of symptoms
| Patient (cycle of RTX) | Indication of first treatment | Delay of relapse (months) | Reappearance of B cell | Indication of retreatment | Dosage | Adverse event 1st treatment/retreatment | Efficacy for systemic symptoms or lymphoma/B cell depletion | RF (UI/ml) before/after | γ-globulin (g/l) before/after | IgG (g/l) before/after | β 2-micro-globulin (mg/l) before/after | Prednisone (mg/day) before/after |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG, immunoglobulin G; IRR, infusion-related reaction; N, no; NA, not available; RF, rheumatoid factor; RTX, rituximab; SSR, serum sickness-like reaction; Y, yes. | ||||||||||||
| 1 (2) | Polysynovitis, cutaneous nodules | 11 | Y | Cutaneous nodules | 4×375 mg/ms | Y (IRR)/N | Y/Y | 405/146 | 23.7/22.2 | 25.6/19.8 | 3.4/3 | 10/0 |
| 2 (2) | Renal, pulmonary, polysynovitis | 8 | Y | Polysynovitis | 2×500 mg/ms | N/N | Y/Y | 1820/65 | 40.8/31.3 | 44.3/31 | 4.4/2.72 | 10/5 |
| 5 (2) | Cryoglobulinaemia | 8 | Y | Cryoglobulinaemia | 1×1 g | N/N | N/Y | 107/144 | 6.6/6.4 | 6/6.2 | 2.2/1.8 | 10/40 |
| 5 (3) | Cryoglobulinaemia | 20 | NA | Cryoglobulinaemia | 2×1 g | N/N | Y/Y | 299/24.3 | 5.1/4 | 6/5.1 | NA/2.4 | 30/10 |
| 10 (2) | Polysynovitis | 12 | Y | Polysynovitis | 1×375 mg/ms | N/Y (SSR) | N/NA | 0/0 | 12.6/NA | 6.1/NA | NA/NA | 10/NA |
| 12 (2) | Cryoglobulinaemia | 22 | Y | Lymphoma | 4×375 mg/ms | N/N | Y/Y | 139/0 | 3/NA | NA/NA | 3.6/NA | 0/0 |